Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.
Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.
*Sign up for news summaries and alerts from 340B Report